The Director, Preclinical Development reports to the Vice President, Preclinical Development and is accountable for timely and effective drug safety support for programs in preclinical or clinical development for AVROBIO’s lentiviral-based gene therapies.
We are looking for an individual to fill this scientific leadership role in Preclinical Development and will be responsible for AVROBIO’s preclinical toxicology and pathology needs. In addition to characterization and oversight of toxicology issues, individuals in this role will also collaborate with the R&D team in establishing hypothesis-driven research aimed at demonstrating efficacy and characterization of toxicity issues related to pharmacology or conditioning. Scientific expertise in biologics or cell and gene therapy drug development, regulatory sciences, and preclinical research is core to this role.
Director, Preclinical Development will supervise the Preclinical Development Team and work cross-functionally to define the preclinical strategy to support lentivirus cell and gene therapy research program, ensuring that AVROBIO considers all appropriate strategic and investigative needs for better lead-candidate selection and characterization of toxicology issues at the time of transition to early development.